Vivek Gupta

Dr. Vivek Gupta

St. John's University
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
PKPoornima Kolhar
Poornima Kolhar
AAAaron C. Anselmo
Aaron C. Anselmo
Vivek GuptaVivek Gupta
Vivek Gupta
KPKapil Pant
Kapil Pant
BPBalabhaskar Prabhakarpandian
Balabhaskar Prabhakarpandian
SMSamir Mitragotri
Samir Mitragotri
Vascular endothelium offers a variety of therapeutic targets for the treatment of cancer, cardiovascular diseases, inflammation, and oxidative stress. Significant research has been focused on developing agents to target the endothelium in diseased tissues. This includes identification of antibodies against adhesion molecules and neovascular expression markers or peptides discovered using phage display. Such targeting molecules also have been used to deliver nanoparticles to the endothelium of the diseased tissue. Here we report, based on in vitro and in vivo studies, that the specificity of endothelial targeting can be enhanced further by engineering the shape of ligand-displaying nanoparticles. In vitro studies performed using microfluidic systems that mimic the vasculature (synthetic microvascular networks) showed that rod-shaped nanoparticles exhibit higher specific and lower nonspecific accumulation under flow at the target compared with their spherical counterparts. Mathematical modeling of particle–surface interactions suggests that the higher avidity and specificity of nanorods originate from the balance of polyvalent interactions that favor adhesion and entropic losses as well as shear-induced detachment that reduce binding. In vivo experiments in mice confirmed that shape-induced enhancement of vascular targeting is also observed under physiological conditions in lungs and brain for nanoparticles displaying anti–intracellular adhesion molecule 1 and anti-transferrin receptor antibodies.

1 October 2019 in Drug Discovery Today
Verified
Journal Article
Closed access
VPVineela Parvathaneni
Vineela Parvathaneni
NKNishant S. Kulkarni
Nishant S. Kulkarni
AMAaron Muth
Aaron Muth
Vivek GuptaVivek Gupta
Vivek Gupta

1 November 2013 in ACS Nano
Verified
Journal Article
Closed access
AAAaron C. Anselmo
Aaron C. Anselmo
Vivek GuptaVivek Gupta
Vivek Gupta
BZBlaine J. Zern
Blaine J. Zern
DPDaniel Pan
Daniel Pan
MZMichael Zakrewsky
Michael Zakrewsky
SMSamir Mitragotri
Samir Mitragotri

10 April 2017 in Nature Nanotechnology
Verified
Journal Article
Closed access
PWPeter Popp Wibroe
Peter Popp Wibroe
AAAaron C. Anselmo
Aaron C. Anselmo
Per NilssonPer Nilsson
Per Nilsson
ASApoorva Sarode
Apoorva Sarode
Vivek GuptaVivek Gupta
Vivek Gupta
Seyed Moein MoghimiSeyed Moein Moghimi
Seyed Moein Moghimi

1 February 2015 in Journal of Controlled Release
Verified
Journal Article
Closed access
AAAaron C. Anselmo
Aaron C. Anselmo
JGJonathan B. Gilbert
Jonathan B. Gilbert
SKSunny Kumar
Sunny Kumar
Vivek GuptaVivek Gupta
Vivek Gupta
RCRobert E. Cohen
Robert E. Cohen
SMSamir Mitragotri
Samir Mitragotri

1 September 2012 in Journal of Controlled Release
Verified
Journal Article
Closed access
BPBrijeshkumar Patel
Brijeshkumar Patel
Vivek GuptaVivek Gupta
Vivek Gupta
FAFakhrul Ahsan
Fakhrul Ahsan